POM-V Prescription Required

Suiseng Coli / C Suspension for Injection for Pigs

Active ingredients: Clostridium novyi, Clostridium perfringens, Escherichia coli

Form

Injection

Species

Pigs

Manufacturer

Laboratorios Hipra SA

VMD MA No.

17533/5015

What it's used for

Piglets: For the passive protection of neonatal piglets by means of the active immunisation of breeding sows and gilts to reduce mortality and clinical sig...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Clostridium novyi + Clostrid...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Suiseng Coli / C Suspension for Injection for Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Piglets: For the passive protection of neonatal piglets by means of the active
immunisation of breeding sows and gilts to reduce mortality and clinical signs of
neonatal enterotoxicosis, such as diarrhoea caused by enterotoxigenic Escherichia
coli
The persistence of these antibodies has not been established.

Revised: January 2025
AN: 02154/2024
For the passive immunisation of neonatal piglets against Necrotic Enteritis by means
of the active immunisation of breeding sows and gilts to induce seroneutralising
antibodies against the of Clostridium perfringens type C.
The persistence of antibodies has not been established.
Sows and gilts: For active immunisation of breeding sows and gilts to induce
seroneutralising antibodies against α-toxin of Clostridium novyi type B. The relevance
of the seroneutralising antibodies was not experimentally determined.
Antibodies have been detected 3 weeks after the completion of the basic vaccination
scheme. The persistence of these antibodies has not been established.

Intramuscular, into the neck muscles.
Dose: 2 ml/animal.
The basic vaccination scheme consists of two doses: the first dose at approximately 6
weeks before farrowing and a second dose at approximately 3 weeks before
farrowing.
It is recommended that the second dose should be given preferably on alternate sides.
Revaccination: on each subsequent gestation, administer one dose 3 weeks before
the expected date of farrowing.
It is advisable to administer the vaccine at a temperature between +15 ºC and +25 ºC.
Shake before use.
To ensure the correct mixing with Suiseng Diff/A, the same volumes of Suiseng Diff/A
and Suiseng Coli/C should be used. All the contents of Suiseng Coli/C should be
transferred into a headspace bottle of Suiseng Diff/A (50 ml bottle with 10 doses, 100
ml bottle with 25 doses and 250 ml bottle with 50 doses).
A pre-sterilised transfer needle can be used according to the following instructions:
-
-
-
-
-
-
Shake well before use. Administer one single dose of 4 ml of the mixed vaccines.

Revised: January 2025
AN: 02154/2024

None.

Very rare: A small granuloma may occur in the muscle tissue at the injection site.
Uncommon: Injection site nodules can be observed, which disappear within 2-3
weeks.
Common: Temperature increase observed at 6 hours post-vaccination (mean 0.4 ºC,
in individual pigs up to 1.2 ºC, uncommonly up to 2 ºC) subsiding without treatment
within 24 hours post-vaccination. Palpable inflammatory local reaction (swelling, not
more than 2 cm
) which resolves without treatment within 5 days post-vaccination.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Revised: January 2025
AN: 02154/2024

Vaccinate healthy animals only

Special precautions for use in animals
Hypersensitivity reactions may occur in sensitive animals. In the event of an
anaphylactic reaction appropriate treatment such as adrenaline should be
administered without delay.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.

Safety and efficacy data are available which demonstrate that this vaccine can be
mixed and administered at one injection site with Suiseng Diff/A. Following
administration of the mixed vaccines, an increase in body temperature (mean 1.43 °C,
not exceeding 1.87 ºC in individual pigs) during the first 6 hours after vaccination
occurs very commonly. Injection site swelling (maximum 4 cm) occurs very commonly,
but typically will resolve within 4 days.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the product mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.

Store and transport refrigerated (2 ºC-8 ºC). Protect from light. Do not freeze.

Revised: January 2025
AN: 02154/2024

Meat and offal: Zero days.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Inactivated bacterial vaccine: Escherichia coli+Clostridial
vaccine.
ATCvet code: QI09AB08.
Stimulates development of protective adhesin-specific antibodies and
seroneutralising antibodies against the heat labile (LT) enterotoxin of
Clostridium perfringens type C and Clostridium novyi type B.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.